iPHEX 2026: Over 600 Overseas Delegates to Connect with Indian Pharma Exporters
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is targeting approximately $1.4 billion in export business opportunities through the 12th edition of the International Exhibition for Pharma and Healthcare (iPHEX 2026), aiming to broaden global market access for Indian drug manufacturers.
What Happened
Organised with support from the Department of Commerce, Ministry of Commerce and Industry, Government of India, iPHEX 2026 is scheduled to take place from 7 to 9 September at Bharat Mandapam in New Delhi. The three-day exhibition and conference will convene more than 800 exhibitors, over 600 international companies, and around 30,000 business visitors, comprising manufacturers, exporters, buyers, distributors, and procurement agencies.
The event is designed around structured buyer–seller meetings to connect Indian exporters directly with international procurement partners. Commercial engagements will center on product sourcing, long-term supply partnerships, contract manufacturing agreements, and technology transfer.
Key Highlights
- Targeted Business Value: Pharmexcil is projecting an estimated $1.4 billion in pharma export opportunities stemming from the event.
- Export Growth Context: The initiative follows a reported 6.8% increase in India’s pharmaceutical exports during the first quarter of FY27 compared to the same period in FY26.
- Broad Participant Base: Over 600 foreign companies and 800 exhibitors will take part, drawing an estimated 30,000 business visitors to Bharat Mandapam.
- Diverse Product Categories: Indian enterprises will display capabilities across active pharmaceutical ingredients (APIs), finished formulations, generics, biologicals, biosimilars, vaccines, and medical devices.
- Global Reach: The event supports trade diversification for an industry whose pharmaceutical products currently reach more than 150 countries.
Why This Matters
The push for international outreach comes amid a complex global trade environment, highlighting the need for Indian suppliers to diversify markets and establish direct relationships with overseas buyers. Industry leaders note that sustaining export momentum depends on translating domestic manufacturing capabilities into global commercial contracts.
Pharmexcil Chairman Namit Joshi highlighted that the growth in pharmaceutical shipments underscores domestic strength across varied product categories, with iPHEX 2026 designed to help Indian firms address international demand. Bhavin Mehta, Vice Chairman of Pharmexcil, noted that significant capacities in APIs, vaccines, biosimilars, and formulations must now be linked to rising global needs. Furthermore, iPHEX Chairman Nipun Jain pointed out that global pharmaceutical trade depends on both trust and capability, positioning the event as a venue to match expanding domestic firms with international partners looking for credible suppliers.
What to Watch Next
The three-day event will run from 7 to 9 September at Bharat Mandapam, New Delhi. Observers will watch the outcomes of the scheduled buyer–seller sessions and whether the commercial negotiations result in the targeted $1.4 billion export volume across traditional formulations, APIs, and high-value categories like biosimilars and vaccines.
Frequently Asked Questions
When and where is iPHEX 2026 being held?
The 12th edition of iPHEX takes place from 7 to 9 September at Bharat Mandapam in New Delhi.
Who is organising iPHEX 2026?
The event is organised by the Pharmaceuticals Export Promotion Council of India (Pharmexcil) with support from the Department of Commerce, Ministry of Commerce and Industry, Government of India.
What export target has been set for iPHEX 2026?
Pharmexcil is targeting approximately $1.4 billion in export business opportunities from the three-day exhibition and conference.
What product segments will be showcased?
Exhibitors will display active pharmaceutical ingredients (APIs), finished formulations, generics, biologicals, biosimilars, vaccines, contract manufacturing capabilities, and medical devices.
Source: BioSpectrum India